Ref number 
Authors 
Candidates medications 
Report 

Year published 

style 
38 
Fujimori S (2011) 
Rebamipide 
CS 
39 
Mizukami K (2011) 
Rebamipide 
CS 
37 
Kurokawa S (2013) 
Rebamipide 
CS 
40 
Fujimori S (2010) 
Rebamipide and misoprostol 
CS 
41 
Watanabe T (2008) 
misoprostol 
CS 
43 
Arakawa T (2012) 
prostaglandin derivatives, mucoprotective drugs, probiotics, and mitochondrial protective drugs 
A 
42 
Takeuchi K (2010) 
Endogenous PGE(2) 
A 
45 
Higuchi K (2009) 
Lansoprazole 
A 
44 
Yoda Y (2010) 
Lansoprazole 
A 
47 
Lim YJ (2012) 
PPIs: no small bowel protective effect 
A 
46 
Zhang S (2013) 
Omeprazole and pantoprazole cannot protect the small intestine from the damage induced by diclofenac 
A 
48 
Amagase K (2010) 
Lafutidine (histamine H(2) receptor antagonist with a mucosal protective action) 
A 
49 
Umegaki E (2010) 
Roxatidine (H(2) receptor antagonist) 
A 
50 
Satoh H (2012) 
Inhibition of acid secretion by antisecretory drugs may exacerbate NSAIDinduced intestinal lesions 
A 
51 
Guslandi M (2012) 
probiotics 
CS 
52 
Satoh H (2010) 
Soluble dietary fibers 
A 
53 
Satoh H (2010) 
Insoluble dietary fiber and soluble dietary fiber 
A 
54 
Sivalingam N (2011) 
Zinc 
A 
55 
Rodríguez de la Serna A (1994) 
Zinc acexamate 
CS 
57 
Wallace JL (1994) 
NOreleasing NSAID 
A 
56 
Takeuchi K (2007) 
Endogenous NO 
A 
3 
Lim YJ (2012) 
Selective COX2 inhibitors (coxibs) 
A 
58 
Maehata Y (2012) 
Selective COX2 inhibitors are not completely safe for the small bowel 
CS 
59 
Fukumoto K (2011) 
TNFα 
A 
60 
LoGuidice A (2012) 
bacterial βDglucuronidase 
A 
61 
LoGuidice A (2010) 
Mitochondrial cyclophilin D 
A 
62 
Kawahara R (2011) 
α7 nicotinic acetylcholine receptors 
A 
63 
Shiotani A (2010) 
geranylgeranylacetone 
CS 
64 
Iwai T (2011) 
Geranylgeranylacetone 
A 
33 
Higashiyama M (2012) 
cilostazol (specific phosphodiesterase (PDE)3 inhibitor) 
A 
65 
Kato N (2009) 
Sildenafil (inhibitor of phosphodiesterase subtype 5) 
A 
66 
Yasuda M (2011) 
Dopamine D2receptor antagonists 
A 
67 
Yanaka A (2013) 
Sulforaphane 
CL 
68 
Menozzi A (2010) 
K(ATP) channel opener diazoxide 
A 
69 
Marchbank T (2008) 
Natural bioactive products (nutriceuticals), such as fish hydrolysates 
CS 
70 
Amagase K (2012) 
Monosodium glutamate 
A 
71 
Chao G (2012) 
Muscovite (natural clay consisting of an insoluble double silicate of aluminum and magnesium) diclofenac 
A 
72 
Davies NM (1997) 
tempo (nitroxide stable free radical scavenger) and metronidazole 
A 